Inventor · disambiguated record
Matthew Mulvey
Also filed as: MULVEY MATTHEW · MULVEY MATTHEW C
10 granted patents·3 pending applications·114 citations·filing 2005–2023
89Inventor score
Top patents by PatentIndex Score
13 records- 0196US7731952B2Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host responseUNIV NEW YORK·Filed 2005·Granted Jun 8, 2010·71 cites·13 claims
- 0291US10105404B2Oncolytic herpes simplex virus and therapeutic uses thereofUNIV NEW YORK·Filed 2017·Granted Oct 23, 2018·9 cites·40 claims
- 0386US8252277B2Virulent oncolytic herpes simplex virus strains engineered to counter the innate host responseMOHR IAN·Filed 2010·Granted Aug 28, 2012·6 cites·11 claims
- 0484US10232003B2Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereofBENEVIR BIOPHARM INC·Filed 2015·Granted Mar 19, 2019·11 cites·23 claims
- 0583US8709397B2Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host responseMOHR IAN·Filed 2012·Granted Apr 29, 2014·7 cites·12 claims
- 0681US9623059B2Oncolytic herpes simplex virus and therapeutic uses thereofMOHR IAN J·Filed 2012·Granted Apr 18, 2017·6 cites·64 claims
- 0778US10456432B2Oncolytic herpes simplex virus and therapeutic uses thereofUNIV NEW YORK·Filed 2018·Granted Oct 29, 2019·1 cites·40 claims
- 0876US7919234B2Methods and compositions for determining the pathogenic status of infectious agentsSEQUELLA INC·Filed 2008·Granted Apr 5, 2011·2 cites·27 claims
- 0975US2022031779A1Oncolytic herpes simplex virus and therapeutic uses thereofUNIV NEW YORK·Filed 2021·Application pending·0 cites
- 1074US11147846B2Oncolytic herpes simplex virus and therapeutic uses thereofUNIV NEW YORK·Filed 2019·Granted Oct 19, 2021·0 cites·23 claims
- 1167US8501400B2Methods and compositions for determining the pathogenic status of infectious agentsMULVEY MATTHEW C·Filed 2011·Granted Aug 6, 2013·1 cites·40 claims
- 1264US2024269203A1Oncolytic virus and uses thereofJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 1362US2024226207A1Universal retargeting of oncolytic hsvJANSSEN BIOTECH INC·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →